NAMS
NewAmsterdam Pharma Company N.V.
$31.68
+0.63
(+2.03%)
Mkt Cap
3.70B
Volume
689,772
52W Range
21.135-42.205
Sector
Healthcare
Beta
0.08
EPS (TTM)
-1.81
P/E Ratio
-20.05
Revenue (TTM)
22.57M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 22.50M | 45.56M | 14.09M | 102.69M | 0 | 0 |
| Net Income | (203.82M) | (241.60M) | (176.94M) | (22.63M) | (41.78M) | (7.02M) |
| EPS | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Free Cash Flow | (148.03M) | (159.24M) | (141.24M) | 10.44M | (29.54M) | (7.36M) |
| FCF / Share | -1.29 | -1.69 | -1.72 | 0.55 | -1.66 | -0.41 |
| Operating CF | (147.78M) | (158.56M) | (141.22M) | 10.66M | (29.51M) | (7.34M) |
| Total Assets | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M | 139.87M |
| Total Debt | 202,000 | 448,000 | 60,000 | 126,000 | 186,511 | 0 |
| Cash & Equiv | 490.00M | 771.74M | 340.45M | 467.73M | 60.38M | 1.37M |
| Book Value | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M | 127.46M |
| Return on Equity | -0.30 | -0.32 | -0.61 | -0.05 | -0.74 | -0.06 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.04M | 32,000 | 348,000 | 19.14M | 2.98M | 12.77M | 29.11M | 2.28M | 1.40M | 803,000 | 2.94M | 1.72M |
| Net Income | (48.44M) | (74.92M) | (72.00M) | (17.36M) | (39.53M) | (92.18M) | (16.65M) | (39.01M) | (93.77M) | (49.49M) | (47.13M) | (38.29M) |
| EPS | -0.40 | -0.65 | -0.61 | -0.15 | -0.34 | -0.98 | -0.18 | -0.41 | -1.06 | -0.52 | -0.56 | -0.43 |
| Free Cash Flow | (30.64M) | (40.98M) | (32.81M) | (37.76M) | (36.48M) | (37.48M) | (12.58M) | (54.19M) | (54.99M) | (33.08M) | (35.33M) | (29.31M) |
| FCF / Share | -0.25 | -0.36 | -0.28 | -0.34 | -0.31 | -0.39 | -0.13 | -0.57 | -0.67 | -0.40 | -0.43 | -0.36 |
| Operating CF | (30.60M) | (40.88M) | (32.77M) | (37.67M) | (36.47M) | (37.48M) | (12.50M) | (53.98M) | (54.60M) | (33.07M) | (35.32M) | (29.30M) |
| Total Assets | 732.64M | 769.28M | 786.43M | 815.11M | 818.41M | 864.62M | 439.19M | 446.69M | 488.46M | 347.10M | N/A | 514.30M |
| Total Debt | 23,000 | 202,000 | 266,000 | 328,000 | 389,000 | 448,000 | 506,000 | 562,000 | 43,000 | 60,000 | N/A | 94,978 |
| Cash & Equiv | 457.61M | 490.00M | 538.41M | 563.86M | 748.42M | 771.74M | 422.73M | 430.71M | 481.15M | 340.45M | N/A | 418.66M |
| Book Value | 665.22M | 683.43M | 728.07M | 778.50M | 777.36M | 757.50M | 378.86M | 387.44M | 411.80M | 288.39M | N/A | 460.99M |
| Return on Equity | -0.07 | -0.11 | -0.10 | -0.02 | -0.05 | -0.12 | -0.04 | -0.10 | -0.23 | -0.17 | N/A | -0.08 |
NAMS News
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates